Bryn Inc. Q2 2026: Going Concern Deepens as Related-Party Debt Swells and Internal Controls Flagged
BRRN filed a Earnings and Guidance on light trading volume (0.3× avg).
Summary
Bryn Inc.'s Q2 2026 10-Q shows no revenue, zero cash, a $212,910 working capital deficit, and a going concern warning. The company is being funded by interest-free loans from its new controlling shareholder, Medo Healthcare LLC, and disclosed four material weaknesses in internal controls.
Key Events · Earnings and Guidance · BRRN
-
Going Concern Warning Reiterated
Management states substantial doubt about the company's ability to continue as a going concern for the next twelve months, citing insufficient operational cash flow and the need to raise additional funds.
-
Zero Cash, No Revenue
The company reported no revenue for the quarter and cash and cash equivalents of $0 as of June 30, 2026. Net loss for the six months was $209,583.
-
Related-Party Debt Increases
Medo Healthcare LLC extended $139,037 in interest-free demand loans during the six months ended June 30, 2026. Total related party loans outstanding were $139,037.
-
Share Issuance to Settle Debt
The company issued 30,015,577 restricted common shares to former custodian David Lazar to cancel $93,285 of debt, with an additional $8,649 debt adjustment in Q2 2026.
Analysis · BRRN · Trade & Services
Bryn Inc.'s Q2 2026 report shows a company with no revenue, zero cash, and a growing reliance on interest-free demand loans from its new controlling shareholder, Medo Healthcare LLC. The working capital deficit widened to $212,910 and the accumulated deficit reached $117.8 million. Management again states substantial doubt about the company's ability to continue as a going concern. The filing also discloses four material weaknesses in internal controls, including no independent board or audit committee and reliance on a financial consultant. The company issued 30 million shares to former custodian David Lazar to settle $93,285 of debt, adding to dilution. With no operations and a plan to acquire pharmaceutical distributors using AI, the company remains a shell with significant survival risk.
At the time of this filing, BRRN was trading at $0.13 on OTC in the Trade & Services sector, with a market capitalization of approximately $59.5M. The 52-week trading range was $0.00 to $9.90. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.